Suppr超能文献

西地那非治疗透析患者勃起功能障碍的初步观察

Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients.

作者信息

Rosas S E, Wasserstein A, Kobrin S, Feldman H I

机构信息

Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Renal, Electrolyte, and Hypertension Division, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

Am J Kidney Dis. 2001 Jan;37(1):134-137. doi: 10.1053/ajkd.2001.20608.

Abstract

Erectile dysfunction is common in dialysis patients. We report our experience with sildenafil citrate in patients undergoing dialysis therapy. Male subjects attending the Outpatient Dialysis Unit at the University of Pennsylvania (Philadelphia, PA) who were prescribed sildenafil by their primary physician or nephrologist were asked to complete the International Index of Erectile Function before their first dose of sildenafil and after at least 4 weeks of therapy. Subjects' mean age was 50.3 +/- 14.63 (SD) years. Ninety-three percent of the subjects were black. Based on a global efficacy question, 66.7% of the subjects believed that treatment had improved their erections. Subjects reported no increase in the sexual desire domain despite experiencing a significant increase in erectile function, orgasmic function, and satisfaction with intercourse. Sildenafil was well tolerated in a selected group of patients who reported improved sexual function with no major adverse effects.

摘要

勃起功能障碍在透析患者中很常见。我们报告了我们在接受透析治疗的患者中使用枸橼酸西地那非的经验。在宾夕法尼亚大学(费城,宾夕法尼亚州)门诊透析科就诊的男性患者,若其初级医师或肾病学家为他们开具了西地那非处方,则被要求在首次服用西地那非之前以及至少治疗4周后完成国际勃起功能指数。受试者的平均年龄为50.3±14.63(标准差)岁。93%的受试者为黑人。基于一个总体疗效问题,66.7%的受试者认为治疗改善了他们的勃起功能。尽管勃起功能、性高潮功能和性交满意度显著提高,但受试者报告性欲方面没有增加。在一组选定的患者中,西地那非耐受性良好,这些患者报告性功能有所改善且无重大不良反应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验